W
Weavr Health Corp
Developed easy-to-use, reliable blood collection devices to ensure anyone, anywhere can access the best health and wellness care
About Weavr Health Corp
Weavr Health Corp., initially incorporated as Boston Microfluidics, Inc. in 2005, operated as a medical device developer focused on democratizing diagnostics through next-generation blood collection technology. The company's core mission was to create user-friendly, reliable devices for at-home blood collection, making testing more accessible and affordable. Weavr Health was acquired by Renegade.bio on March 23, 2023.
The company developed a portfolio of products designed to enable any adult user to collect high-quality, clinical-grade blood samples without the need for a phlebotomist or specialized laboratory equipment. Its flagship product, the Velvet™ blood collection device, was engineered to consistently collect a specific volume of whole blood and separate the sample into plasma and red blood cells. This process allows for more complex analysis and ensures sample stability at room temperature for an extended period, which simplifies logistics for lab transport. Another product, the Silk™ COVID-19 Rapid Antibody Test, was developed to provide rapid, qualitative detection of COVID-19 antibodies. The business model centered on supplying these devices to diagnostic laboratories, healthcare providers, and direct-to-consumer health companies. A significant partnership was established with Labcorp, which utilized the Velvet™ device for its Labcorp OnDemand at-home diabetes risk test, measuring HbA1c from a small blood sample. The collaboration involved an equity investment from Labcorp and resulted in the test being available nationwide after receiving approval from the New York State Clinical Laboratory Evaluation Program.
Before its acquisition, Weavr Health had raised a total of $24.2M in funding through multiple rounds, including investments from Anzu Partners and Labcorp Venture Fund. In January 2023, Nightingale Health acquired a worldwide license and rights to the Velvet™ device, allowing them to manufacture and use it in their preventative health services, having previously been a distributor. This move was strategic for Nightingale to integrate the self-collection technology more tightly into its global service delivery.
Source: Dealroom company dataNews
Open roles
Weavr Health Corp in the Cambridge ecosystem
The Weavr Health Corp office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Anzu Partners
LabCorp
Series B and later1 investor entered at this stage
Nightingale Health
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Weavr Health Corp on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Weavr Health Corp on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


